Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
1.500
+0.150 (11.11%)
Sep 9, 2024, 4:00 PM EDT - Market closed
Mersana Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Revenue | 29.94 | 36.86 | 26.58 | 0.04 | 0.83 | 42.12 | Upgrade
|
| Revenue Growth (YoY) | -22.68% | 38.65% | 61716.28% | -94.81% | -98.03% | 297.61% | Upgrade
|
| Cost of Revenue | 87.96 | 148.27 | 173.39 | 132.01 | 67.04 | 55.04 | Upgrade
|
| Gross Profit | -58.02 | -111.41 | -146.8 | -131.97 | -66.21 | -12.92 | Upgrade
|
| Selling, General & Admin | 45.09 | 59.54 | 56.96 | 36.89 | 21.9 | 17.28 | Upgrade
|
| Operating Expenses | 45.09 | 59.54 | 56.96 | 36.89 | 21.9 | 17.28 | Upgrade
|
| Operating Income | -103.11 | -170.96 | -203.77 | -168.86 | -88.11 | -30.2 | Upgrade
|
| Interest Expense | -4.05 | -4.07 | -3.33 | -1.27 | -0.36 | -0.23 | Upgrade
|
| Interest & Investment Income | 11.1 | 12.07 | 2.88 | 0.07 | 0.42 | 2.23 | Upgrade
|
| EBT Excluding Unusual Items | -96.06 | -162.96 | -204.21 | -170.06 | -88.05 | -28.21 | Upgrade
|
| Merger & Restructuring Charges | -8.71 | -8.71 | - | - | - | - | Upgrade
|
| Pretax Income | -104.77 | -171.67 | -204.21 | -170.06 | -88.05 | -28.21 | Upgrade
|
| Net Income | -104.77 | -171.67 | -204.21 | -170.06 | -88.05 | -28.21 | Upgrade
|
| Net Income to Common | -104.77 | -171.67 | -204.21 | -170.06 | -88.05 | -28.21 | Upgrade
|
| Shares Outstanding (Basic) | 121 | 116 | 94 | 71 | 61 | 43 | Upgrade
|
| Shares Outstanding (Diluted) | 121 | 116 | 94 | 71 | 61 | 43 | Upgrade
|
| Shares Change (YoY) | 14.96% | 23.98% | 32.69% | 14.79% | 41.37% | 88.83% | Upgrade
|
| EPS (Basic) | -0.86 | -1.48 | -2.18 | -2.41 | -1.43 | -0.65 | Upgrade
|
| EPS (Diluted) | -0.86 | -1.48 | -2.18 | -2.41 | -1.43 | -0.65 | Upgrade
|
| Free Cash Flow | -133.55 | -171.05 | -51.56 | -140.64 | -75.17 | -68.35 | Upgrade
|
| Free Cash Flow Per Share | -1.10 | -1.47 | -0.55 | -1.99 | -1.22 | -1.57 | Upgrade
|
| Gross Margin | -193.81% | - | - | - | - | -30.66% | Upgrade
|
| Operating Margin | -344.43% | -463.86% | -766.59% | -392693.02% | -10641.30% | -71.69% | Upgrade
|
| Profit Margin | -349.98% | -465.80% | -768.26% | -395488.37% | -10633.45% | -66.97% | Upgrade
|
| Free Cash Flow Margin | -446.09% | -464.12% | -193.97% | -327060.47% | -9078.38% | -162.26% | Upgrade
|
| EBITDA | -101.41 | -169.44 | -202.84 | -168 | -87.1 | -28.96 | Upgrade
|
| EBITDA Margin | - | - | - | - | - | -68.74% | Upgrade
|
| D&A For EBITDA | 1.7 | 1.52 | 0.93 | 0.86 | 1.01 | 1.25 | Upgrade
|
| EBIT | -103.11 | -170.96 | -203.77 | -168.86 | -88.11 | -30.2 | Upgrade
|
| EBIT Margin | - | - | - | - | - | -71.69% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.